SPI Healthcare
3.597,97
PKT
+5,14
PKT
+0,14
%
Werbung
Leider sind zu diesem Wert keine aktuellen Kursdaten verfügbar, die Stammdaten finden Sie im unteren Seitenbereich.
Analysen zu SPI Healthcare-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 20.11.12 | Novartis outperform | Exane-BNP Paribas SA | |
| 20.11.12 | Novartis buy | Sarasin Research | |
| 16.11.12 | Novartis outperform | Exane-BNP Paribas SA | |
| 15.11.12 | Novartis buy | UBS AG | |
| 15.11.12 | Novartis outperform | Sanford C. Bernstein and Co., Inc. | |
| 14.11.12 | Sonova neutral | UBS AG | |
| 14.11.12 | Sonova overweight | J.P. Morgan Cazenove | |
| 14.11.12 | Sonova underperform | Exane-BNP Paribas SA | |
| 14.11.12 | Sonova buy | Vontobel Research | |
| 13.11.12 | Sonova buy | Vontobel Research | |
| 13.11.12 | Sonova neutral | Sarasin Research | |
| 12.11.12 | Novartis outperform | Credit Suisse Group | |
| 12.11.12 | Sonova underperform | Exane-BNP Paribas SA | |
| 08.11.12 | Novartis reduce | Vontobel Research | |
| 08.11.12 | Novartis outperform | Sanford C. Bernstein and Co., Inc. | |
| 07.11.12 | Sonova equal-weight | Morgan Stanley | |
| 07.11.12 | Novartis reduce | Vontobel Research | |
| 06.11.12 | Novartis neutral | J.P. Morgan Cazenove | |
| 05.11.12 | Novartis neutral | Citigroup Corp. | |
| 06.11.12 | Novartis outperform | Exane-BNP Paribas SA | |
| 01.11.12 | Straumann underperform | Exane-BNP Paribas SA | |
| 01.11.12 | Lonza hold | Vontobel Research | |
| 31.10.12 | Straumann neutral | Nomura | |
| 31.10.12 | Straumann buy | Deutsche Bank AG | |
| 31.10.12 | Straumann hold | Vontobel Research | |
| 31.10.12 | Lonza hold | Vontobel Research | |
| 30.10.12 | Novartis buy | Deutsche Bank AG | |
| 30.10.12 | Straumann underperform | Cheuvreux SA | |
| 30.10.12 | Straumann neutral | Sarasin Research | |
| 30.10.12 | Straumann hold | Vontobel Research | |
| 29.10.12 | Novartis halten | Independent Research GmbH | |
| 29.10.12 | Sonova buy | Vontobel Research | |
| 29.10.12 | Novartis outperform | Credit Suisse Group | |
| 26.10.12 | Novartis outperform | Exane-BNP Paribas SA | |
| 26.10.12 | Novartis buy | Société Générale Group S.A. (SG) | |
| 26.10.12 | Novartis reduce | Vontobel Research | |
| 25.10.12 | Straumann underperform | Exane-BNP Paribas SA | |
| 25.10.12 | Novartis buy | Sarasin Research | |
| 25.10.12 | Novartis reduce | Vontobel Research | |
| 24.10.12 | Novartis underperform | Cheuvreux SA |